Safety and Efficacy of Regional Citrate Anticoagulation During Sustained Low-Efficiency Dialysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001582

Enrollment

Unknown

Registered

2011-09-13

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute/chronic renal failure

Interventions

A:SLED with calcium-free dialysate and citrate

B:SLED with calcium-containing dialysate and heparin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: With the need of renal replacement therapy because of acute/chronic renal failureAcute renal failure (ARF): 1. ARF combined with hyperkalemia, acidosis, pneumonedema; 2. ARF combined with heart failure; 3. ARF combined with encephaledema; 4. ARF combined with high catabolism; 5. ARF combined with ARDS; 6. Hemodynamic instability; 7. After cardiosurgery; 8. SepsisChronic renal failure under maintenance hemodialysis: (1) acute pneumonedema; (2) Hemodynamic instability; (3) severe edema.

Exclusion criteria

Exclusion criteria: 1. Less than 18 years old; 2. Hypercalemia (serum total calcium > 2.6mmol/L); 3. Citrate acid can't be metabolized efficiently because of severe hyoxemia, hepatic renal failure and muscle hypoperfusion; 4. With the need of additional anticoagulant or hemostasis drug in the treatment; 5. HIV infection; 6. Pregnancy, organ transplantation recipient within 1 year or cachexia; 7. Allergy of cardiopulmonary circulation, anticoagulant or blood purification equipments; 8. Cannot undergo blood purification treatment because of other diseases or having severe complications during treatment; 9. Cannot cooperate effectively during treatment; 10. Involved in other clinical trails; 11. Considered not suitable for the trail by doctors (at least 2 attendings).

Design outcomes

Primary

Measure	Time frame
Coagulation indexes (APTT, PT, PLT);Survival rate of patients in 30 and 60 days;iCa2+ of peripheral blood and blood gas in 0, 2, 6 h;Trans-membrane, arterial and venous pressure;Lifetime of dialyzer and pipeline;Blood-clotting degree of dialyzer (I, II, III, IV);Adverse reactions (systemic and local's hemorrhage, hypocalcemia/ hypercalcemia, acidosis/ alkalosis;Citrate concentration in 0, 2, 6hours (Venous, arterious);Value of PH and BE in 0, 2, 6 hours;The relationship between Citrate concentration and related PH value and iCa2+;	—

Measure

Time frame

Coagulation indexes (APTT, PT, PLT);Survival rate of patients in 30 and 60 days;iCa2+ of peripheral blood and blood gas in 0, 2, 6 h;Trans-membrane, arterial and venous pressure;Lifetime of dialyzer and pipeline;Blood-clotting degree of dialyzer (I, II, III, IV);Adverse reactions (systemic and local's hemorrhage, hypocalcemia/ hypercalcemia, acidosis/ alkalosis;Citrate concentration in 0, 2, 6hours (Venous, arterious);Value of PH and BE in 0, 2, 6 hours;The relationship between Citrate concentration and related PH value and iCa2+;

—

Countries

China

Contacts

Public ContactPing Fu,Ling Zhang

fupinghx@163.com+86 18980601201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026